BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Qsymia (phentermine/topiramate) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Qsymia (phentermine/topiramate)\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06854614-125@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Qsymia (phentermine/topiramate): Phase 4 readout est. (NCT06854614)
DESCRIPTION:Qsymia (phentermine/topiramate)\, phase 4\, Obesity.\nStudy: Se
 quential Therapy Anti-obesitY Medication With Muscle Preservation for Weig
 ht Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEA
 N Trial)\nEstimated primary completion: 28 April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/phentermine-topiramate#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06854614
URL:https://assetmemo.bio/drug/phentermine-topiramate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07213466-125@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Qsymia (phentermine/topiramate): Phase 4 readout est. (NCT07213466)
DESCRIPTION:Qsymia (phentermine/topiramate)\, phase 4\, Obesity.\nStudy: In
 dividualized Pharmacological Approach to Obesity in Patients With Bipolar 
 Disorder\nEstimated primary completion: 1 February 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/phentermine-topiramate#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07213466
URL:https://assetmemo.bio/drug/phentermine-topiramate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790913-125@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Qsymia (phentermine/topiramate): Phase 2 readout est. (NCT07790913)
DESCRIPTION:Qsymia (phentermine/topiramate)\, phase 2\, Obesity.\nStudy: Ob
 esity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia a
 nd Lymphoma\nEstimated primary completion: August 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/phentermine-topiramate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07790913
URL:https://assetmemo.bio/drug/phentermine-topiramate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06905626-125@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Qsymia (phentermine/topiramate): Phase 3 readout est. (NCT06905626)
DESCRIPTION:Qsymia (phentermine/topiramate)\, phase 3.\nStudy: Weight Gain 
 Prevention in Adolescents and Young Adults\nEstimated primary completion: 
 31 October 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/phen
 termine-topiramate#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06905626
URL:https://assetmemo.bio/drug/phentermine-topiramate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
